Literature DB >> 23939895

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

A Walkty1, J A Karlowsky, H Adam, M Baxter, P Lagacé-Wiens, D J Hoban, G G Zhanel.   

Abstract

The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90 values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by ≤8 μg/ml of ceftolozane-tazobactam.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23939895      PMCID： PMC3811242          DOI： 10.1128/AAC.01404-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Yoshikazu Ishii; Kazuo Hatano; Kazuhiro Tateda; Keizo Yamaguchi
Journal:  Int J Antimicrob Agents       Date:  2007-07-17       Impact factor: 5.283

3.  Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Authors:  Thomas P Lodise; Nimish Patel; Andrea Kwa; Jeffrey Graves; Jon P Furuno; Eileen Graffunder; Ben Lomaestro; Jessina C McGregor
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

5.  In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Toru Nakai; Yoshimi Wakai; Fumiaki Ikeda; Kazuo Hatano
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

6.  Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.

Authors:  M Tumbarello; E Repetto; E M Trecarichi; C Bernardini; G De Pascale; A Parisini; M Rossi; M P Molinari; T Spanu; C Viscoli; R Cauda; M Bassetti
Journal:  Epidemiol Infect       Date:  2011-11       Impact factor: 2.451

7.  Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

Authors:  D Mathai; R N Jones; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

8.  Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.

Authors:  Helio S Sader; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

9.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

10.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803
View more
  19 in total

1.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.

Authors:  Yu Mi Wi; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Kwan Soo Ko; Kyong Ran Peck; Jae-Hoon Song; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Jose M Munita; Samuel L Aitken; William R Miller; Federico Perez; Rossana Rosa; Luis A Shimose; Paola N Lichtenberger; Lilian M Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T Tran; Javier Adachi; Robert Rakita; Samuel Shelburne; Robert A Bonomo; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

5.  Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Adam L Bailey; Tom Armstrong; Hari-Prakash Dwivedi; Gerald A Denys; Janet Hindler; Shelley Campeau; Maria Traczewski; Romney Humphries; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

Review 6.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 7.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

8.  Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.

Authors:  Benjamin Miller; Myra W Popejoy; Ellie Hershberger; Judith N Steenbergen; John Alverdy
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 9.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

10.  Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.

Authors:  Seetha M Tamma; Alice J Hsu; Pranita D Tamma
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.